Pegylated-Interferon and Ribavirin for Chronic Hepatitis C Virus Infection in Decompensated Cirrhotics Awaiting Liver Transplantation
The Open Transplantation Journal · 2011
DOI: 10.2174/1874418401105010032 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Open Transplantation Journal, 2011. Verfasst von B.E. Annicchiarico.
Abstract (Originalsprache)
Sustained virologic response (SVR) to the antiviral therapy for chronic hepatitis C virus infection before liver transplantation (LT) can prevent graft infection.Pegylated (PEG)-interferon (IFN) may ameliorate the SVR, improving the risk-to-benefit ratio of antiviral therapy in cirrhotics awaiting LT.From January 2001 to March 2009, 21 HCVinfected cirrhotics eligible for LT were treated with PEG-IFN alpha-2b (1.5 µg/kg weight/week) and ribavirin (800-1200 mg/day).Mean age was 53.7±7.9 years.There were 11 men.Eleven had genotype 1b.Child-Pugh score was 9.5±1.2,Model for End-Stage Liver Disease score 16.6±1.8.Besides virologic failure, full dosage and planned length of therapy were tolerated in 5 patients (23.8%).Adverse events occurred in all patients, life-threatening in 9 (42.9%).No patient died during treatment.Adverse events caused treatment withdrawal in 11 patients (52.4%), ribavirin and/or PEG-IFN reduction in 7 (33.3%).On an intention-to-treat basis, SVR was obtained in 4 patients (19.0%).None of the genotype 1 or 3 patients obtained SVR; 50.0% of genotype 2 patients obtained SVR.All patients with SVR experienced rapid virological response (RVR).Six patients (three nonresponders, two relapsers, one sustained responder) were transplanted; six died; four are awaiting LT; two are under evaluation for listening; three refused LT.The risk-to-benefit ratio is against treatment with PEG-IFN and ribavirin of severely decompensated genotype 1 cirrhotics.In contrast, antiviral therapy is probably beneficial in genotype 2 subjects, due to an expected SVR rate of 50%.However, one must carefully consider the high risk for severe adverse events.
Zitieren
APA
Annicchiarico, B. (2011). Pegylated-Interferon and Ribavirin for Chronic Hepatitis C Virus Infection in Decompensated Cirrhotics Awaiting Liver Transplantation. The Open Transplantation Journal. https://doi.org/10.2174/1874418401105010032
Vancouver
Annicchiarico B. Pegylated-Interferon and Ribavirin for Chronic Hepatitis C Virus Infection in Decompensated Cirrhotics Awaiting Liver Transplantation. The Open Transplantation Journal. 2011. doi:10.2174/1874418401105010032
BibTeX
@article{Annicchiarico2011,
author = {Annicchiarico, B.E.},
title = {Pegylated-Interferon and Ribavirin for Chronic Hepatitis C Virus Infection in Decompensated Cirrhotics Awaiting Liver Transplantation},
journal = {The Open Transplantation Journal},
year = {2011},
doi = {10.2174/1874418401105010032}
}
EUVIMED